MIRA Pharmaceuticals, Inc.
MIRA
$1.07
$0.172819.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.22% | 22.31% | 87.70% | 44.30% | 47.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.96% | 26.69% | 77.75% | 29.48% | 20.97% |
| Operating Income | 5.96% | -26.69% | -77.75% | -29.48% | -20.97% |
| Income Before Tax | 34.46% | -48.99% | -121.67% | -78.49% | -69.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.46% | -48.99% | -121.67% | -78.49% | -69.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.46% | -48.99% | -121.67% | -78.49% | -69.76% |
| EBIT | 5.96% | -26.69% | -77.75% | -29.48% | -20.97% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 41.58% | -52.58% | -143.24% | -89.34% | -72.17% |
| Normalized Basic EPS | 41.56% | -52.65% | -143.34% | -89.36% | -72.19% |
| EPS Diluted | 41.58% | -52.58% | -143.24% | -89.34% | -72.17% |
| Normalized Diluted EPS | 41.56% | -52.65% | -143.34% | -89.36% | -72.19% |
| Average Basic Shares Outstanding | 11.16% | -14.75% | -16.12% | -17.84% | -15.15% |
| Average Diluted Shares Outstanding | 11.16% | -14.75% | -16.12% | -17.84% | -15.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |